Duelks Robert N 4

4 · BROADRIDGE FINANCIAL SOLUTIONS, INC. · Filed Feb 26, 2025

Form 4

Period: 2025-02-26

Director

Transactions

Exercise/Conversion
Stock Option (Right to Buy)
2025-02-26−5,771→ 0 total
Exercise: $56.37From: 2015-11-12Exp: 2025-11-12→ Common Stock (5,771 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-02-26−4,753→ 0 total
Exercise: $64.89From: 2016-11-17Exp: 2026-11-17→ Common Stock (4,753 underlying)
Exercise/Conversion
Common Stock
2025-02-26$56.37/sh+5,771$325,311→ 26,055 total
Sale
Common Stock
2025-02-26$237.15/sh−2,574$610,432→ 32,341 total
Exercise/Conversion
Common Stock
2025-02-26$88.66/sh+4,107$364,127→ 34,915 total
Sale
Common Stock
2025-02-26$237.15/sh−2,690$637,942→ 29,651 total
Exercise/Conversion
Common Stock
2025-02-26$64.89/sh+4,753$308,422→ 30,808 total
Sale
Common Stock
2025-02-26$237.15/sh−3,141$744,898→ 26,510 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-02-26−4,107→ 0 total
Exercise: $88.66From: 2017-11-16Exp: 2027-11-16→ Common Stock (4,107 underlying)

Holdings

Footnotes (1)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.01 - $237.41, inclusive. The reporting person undertakes to provide to Broadridge Financial Solutions, Inc., any shareholder of Broadridge Financial Solutions, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

Documents

1 file